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Summary Triclabendazole is the drug of choice against Fasciola hepatica infections in humans
and animals. However, parasite resistance against triclabendazole is spreading in the veterinary
ﬁeld, and there are no drugs of comparable activity currently available for the treatment and
control of fascioliasis. We investigated the efﬁcacy of single oral doses of artemether and OZ78
against adult triclabendazole-resistant F. hepatica harboured in rats, and compared the results
with triclabendazole administered at two different doses. Single oral doses of 100mg/kg OZ78
and 200mg/kg artemether resulted in worm burden reductions of 100%. Whereas a single
10mg/kg dose of triclabendazole achieved a worm burden reduction of only 4.0%, a ﬁve-fold
higher dose yielded a signiﬁcant worm burden reduction of 60.9%. However, the lower dose of
triclabendazole administered to rats harbouring a triclabendazole-sensitive F. hepatica isolate
resulted in a worm burden reduction of 95.3%. Our ﬁndings conﬁrm that artemether and
OZ78 possess good fasciocidal properties, even against a triclabendazole-resistant F. hepatica
isolate, and hence these drugs might become useful in areas where triclabendazole resistance
is common.
opica© 2007 Royal Society of Tr
reserved.1. Introduction
Fascioliasis is a zoonotic disease caused by an infection
with the liver ﬂukes Fasciola hepatica and/or F. gigantica.
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lthough fascioliasis belongs to the so-called neglected trop-
cal diseases (Hotez et al., 2006), it is a considerable public
ealth problem and of even greater veterinary importance.
n estimated 91 million people are at risk of fascioliasis,
nd up to 17 million people might be infected (Keiser and
tzinger, 2005; WHO, 1995). In livestock, there are signif-
cant economic losses due to growth retardation, reduced
ilk yield and impaired animal fertility (Schweizer et al.,
005).
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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gFigure 1 Chemical structures of
In veterinary medicine, triclabendazole is the most com-
only used drug against fascioliasis, due to the high activity
f the drug against both juvenile and adult stages of
he parasite. Other veterinary fasciolicides, such as clor-
ulon, closantel, nitroxynil and albendazole, lack activity
gainst the juvenile stages of F. hepatica and F. gigantica
Fairweather and Boray, 1999). The young developing F. hep-
tica migrate through the liver parenchyma and thus cause
xtensive haemorrhaging and ﬁbrosis of the liver (Behm and
angster, 1999). Treatment of human fascioliasis relies pri-
arily on triclabendazole, but the drug is registered in only
our countries (Keiser et al., 2005).
Field isolates of F. hepatica resistant to triclabenda-
ole were ﬁrst described in Australian livestock in the
id-1990s, and resistance is now spreading across Europe.
ost recently, triclabendazole resistance has been reported
n Spain (Alvarez-Sanchez et al., 2006; Fairweather, 2005;
eiser et al., 2005). Although triclabendazole resistance has
ot been reported in human infections thus far, it might just
e a matter of time, as humans are likely to become infected
ith Fasciola metacercariae of animal origin (Coles, 2006).
There is a pressing need to develop new fascioci-
al drugs that are active against all parasite stages.
few promising compounds have been discovered in
he recent past. For example, a derivative of triclaben-
azole, namely 5-chloro-2methylthio-6-(1-naphthyloxy)-1H-
enzimidazole (compound alpha) showed high activity in
itro and in vivo (Ibarra et al., 2004; Vera Montenegro et al.,
004). Compound alpha, however, failed to show any activ-
ty against a triclabendazole-resistant F. hepatica infection
n lambs (McCoy et al., 2006). We have recently reported
he fasciocidal properties of the antimalarials artemether
nd artesunate and of a synthetic 1,2,4-trioxolane (OZ78);
n the F. hepatica—rat model. We found that single oral doses
f 200mg/kg artemether and 100mg/kg OZ78 resulted in
orm burden reductions of 100% against both juvenile and
dult F. hepatica (Keiser et al., 2006a, 2006b).
The aim of the present study was to determine the
fﬁcacy of single oral artemether and OZ78 against adult
riclabendazole-resistant ﬂukes harboured in rats. Our
esults are compared with those for triclabendazole, admin-
stered at two different doses.
. Materials and methods.1. Drugs
Z78 was synthesized at the College of Pharmacy, Uni-
ersity of Nebraska Medical Center (Nebraska, NE, USA).
rtemether was the gift of Kunming Pharmaceutical
a
d
s
cether, OZ78 and triclabendazole.
o-operation (Kunming, China). Triclabendazole was
btained from Novartis Animal Health Ltd (Basel, Switzer-
and) and the commercial drench (5% Fasinex, Novartis
nimal Health Ltd) was used. The chemical structures of
he three drugs are presented in Figure 1. Compounds were
repared as suspensions in 7% (v/v) Tween-80 and 3% (v/v)
thanol before oral administration.
.2. Ethical clearance, parasites and host—parasite
odels
ll animal studies presented here were approved by national
egulatory authorities in Switzerland and the UK. Female
istar rats (n = 24; age, 5 weeks; weight, ∼100 g) were
urchased from RCC (Itingen, Switzerland). Adult male
prague-Dawley rats (n = 16; age, 9 weeks; weight, ∼320 g)
ere bred in the Animal House at Queen’s University of
elfast (Belfast, Northern Ireland). Rats were housed in
roups of no more than four in Macrolon cages under envi-
onmentally controlled conditions (temperature, ∼25 ◦C;
umidity, ∼70%; 12 h light/dark cycle); they were acclima-
ized for 1 week and had free access to water and rodent
ood.
Metacercariae (Oberon isolate) of F. hepatica were pro-
uced from infections of the snail Galba truncatula using
outine procedures in our laboratories at Queen’s University
f Belfast, Belfast, Northern Ireland (Walker et al., 2006).
he metacercariae used for the experiments were from the
ame batch and were stored no longer than 16 weeks prior
o use. The Oberon isolate was identiﬁed in 1999 in Oberon,
ustralia, where low cure rates had been reported in sheep
ollowing triclabendazole treatment. It has since been kept
n the laboratory. Metacercariae of the Cullompton isolate
triclabendazole-sensitive) were purchased from Mr G. Gra-
am (Addlestone, UK).
Thirty and ten rats were each infected intragastrically
ith 20—25 metacercarial cysts of the Oberon and Cullomp-
on isolates of F. hepatica, respectively.
Twelve to ﬁfteen weeks post-infection, rats infected with
he Oberon isolate were treated orally with artemether
200mg/kg) and OZ78 (100mg/kg). Two groups of rats
eceived triclabendazole at 10mg/kg and 50mg/kg, respec-
ively. Four (for triclabendazole) and six (for artemether
nd OZ78) untreated rats, respectively, served as control
roups.Four rats infected with the Cullompton isolate of F. hep-
tica received triclabendazole at a single 10mg/kg oral
ose 12 weeks post-infection. Six rats infected with the
ame isolate remained untreated, and hence served as
ontrols.
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Table 1 Worm burden reductions of adult Fasciola hepatica harboured in rats (Cullompton isolate) following the administration
of triclabendazole
Treatment Dose
(mg/kg)
No. rats
investigated
No. rats
cureda
Mean worm
burden (SD)
Total worm burden
reduction (%)
Kruskal-Wallis
test
P-value
5.3 (
0.25
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tControl — 6 —
Triclabendazole 10 4 3
a The number of rats without ﬂukes.
Ten to 17 days post-treatment, rats were euthanized
by CO2. At necropsy F. hepatica were harvested from the
excised bile ducts and counted.
2.3. Statistical analysis
Statistical analysis was performed with version 2.4.5 of
Statsdirect statistical software (Statsdirect Ltd, Cheshire,
UK). Average worm burdens were expressed as arithmetic
means, including values of zero for animals with no worms.
We used the Kruskal-Wallis (KW) test to compare the
medians of the responses between the treatment and the
matching control group. A difference in median was consid-
ered to be signiﬁcant at a level of 5%.
3. Results and discussion
Table 1 shows that administration of a single 10mg/kg
oral dose of triclabendazole to rats harbouring an adult
triclabendazole-sensitive F. hepatica infection, resulted in
a worm burden reduction of 95.3% (KW=6.75; P = 0.009).
This ﬁnding is in accordance with previous studies with
triclabendazole-susceptible F. hepatica isolates, which
reported complete worm burden reductions with 10mg/kg
single oral doses of triclabendazole (Boray et al., 1983;
Turner et al., 1984).
However, triclabendazole at a single 10mg/kg oral
dose failed to show a signiﬁcant effect against the
triclabendazole-resistant Oberon isolate of F. hepatica; a
low worm burden reduction of only 4.0% was observed
(Table 2). At a ﬁve-fold higher dose of triclabendazole, we
observed a statistically signiﬁcant worm burden reduction
b
g
X
f
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Table 2 Worm burden reductions of adult Fasciola hepatica harb
triclabendazole, OZ78 and artemether
Treatment Dose
(mg/kg)
No. rats
investigated
No. rats
cureda
Mean
burde
Control 1 — 4b — 6.25
Triclabendazole 10 4b 0 6.0 (2
Control 2 — 4c — 5.75
Triclabendazole 50 4c 0 2.25
Control 3 — 6d — 4.2 (1
OZ78 100 4d 4 0
Artemether 200 4d 4 0
a The number of rats without ﬂukes.
b First experiment.
c Second experiment.
d Third experiment.1.9) — — —
(0.5) 95.3 6.75 0.009
f 60.9% in rats infected with the triclabendazole-resistant
. hepatica isolate (KW=5.40; P = 0.020).
The lack of activity of triclabendazole against the Oberon
solate in rats with a standard dose of 10mg/kg conﬁrms
ecent ﬁndings obtained in sheep; a single 10mg/kg oral
ose of triclabendazole administered to sheep infected with
his triclabendazole-resistant strain of F. hepatica showed an
fﬁcacy below 5% against 2- and 4-week-old ﬂukes (Walker
t al., 2004).
Importantly, we found that both artemether and
Z78 were highly efﬁcacious against this triclabendazole-
esistant isolate of F. hepatica; administration of single oral
oses of 100mg/kg OZ78 or 200mg/kg artemether resulted
n worm burden reductions of 100% (KW=7.2; P = 0.007).
n view of our recent ﬁndings that single oral doses of
00mg/kg OZ78 and 200mg/kg artemether administered to
ats infected with a triclabendazole-sensitive F. hepatica
solate achieved 100% worm burden reductions (Keiser et
l., 2006a, 2006b), there is no apparent difference between
he fasciocidal efﬁcacy of artemether and OZ78 against the
riclabendazole-resistant and the triclabendazole-sensitive
solates. The most likely explanation of this ﬁnding arises
y different mechanisms of actions of these peroxidic drugs
hen compared with triclabendazole. It has been demon-
trated that triclabendazole disrupts microtubule-based
ecretory processes in the liver ﬂukes (Fairweather, 2005;
airweather and Boray, 1999). The mechanism of action of
he artemisinins on trematodes remains to be elucidated,
ut in vitro studies with F. hepatica and schistosomes sug-
est that haemin plays a role (Keiser and Utzinger, in press;
iao et al., 2001). A long-standing hypothesis to account
or the antimalarial speciﬁcity of the artemisinins is that
he peroxide bond undergoes reductive activation by haem
oured in rats (Oberon isolate) following the administration of
worm
n (SD)
Total worm burden
reduction (%)
Kruskal-Wallis
test
P-value
(1.9) — — —
.2) 4.0 0.09 0.764
(1.7) — — —
(1.0) 60.9 5.40 0.020
.7) — — —
100 7.20 0.007
100 7.20 0.007
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eleased by parasite Hb digestion producing carbon-centred
ree radicals (Golenser et al., 2006). Another likely target
f the artemisinins is the PfATP6, a SERCA-type Ca2+-ATPase
Eckstein-Ludwig et al., 2003). As Plasmodium, Schistosoma
pp. and Fasciola spp. degrade Hb to generate free haem,
similar mechanism of action of the artemisinins might be
nvolved in the death of these parasites.
In conclusion, we have shown that artemether and OZ78
ave good activities against a triclabendazole-resistant
. hepatica isolate. If studies in larger animals and
xploratory clinical trials conﬁrm the fasciocidal properties
f artemether and OZ78, these drugs might emerge as alter-
ative broad-spectrum fasciocidal drugs, which would be
articularly useful in areas where triclabendazole resistance
s common.
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